NACE - National Association for Continuing Education’s Post

ACELYRIN, INC. announced positive top-line results from its global Phase 2b/3 clinical trial of izokibep in psoriatic arthritis (PsA). Izokibep met its primary endpoint of ACR50 at week 16 by showing a high statistical significance. Results from the 160 mg weekly (QW) and every other week (Q2W) arms showed improved magnitude of responses on higher hurdle endpoints such as ACR70, PASI100, and Minimal Disease Activity relative to the Phase 2 80 mg Q2W dose. Izokibep also showed to be well-tolerated with a favorable safety profile which remains consistent with the IL-17A class. Izokibep is being evaluated in multiple late-stage trials in moderate-to-severe HS, PsA, and uveitis, with plans to initiate an additional Phase 3 program in axial spondyloarthritis (AxSpA). #Rheumatology #Dermatology #PsoriaticArthritis #PsA #HidradenitisSuppurativa #HS #ACELYRIN #izokibep Read more: https://lnkd.in/eet-y-hR

Eli Lilly and Company announced that the FDA has approved EBGLYSS™ (lebrikizumab-lbkz), an IL-13 inhibitor, for treating moderate-to-severe atopic dermatitis (eczema) in patients 12 years and older who are not well-controlled with topical therapies.    The approval is based on the ADvocate and ADhere studies, offering a new treatment option for those with hard-to-control eczema symptoms. EBGLYSS reduces inflammation and symptoms like dry, itchy skin. Clinical trials showed 38% of patients achieved clearer skin by Week 16, with many experiencing itch relief as early as two weeks.    Read more: https://lnkd.in/eEbQXZFD   #Dermatology #AtopicDermatitis #Eczema

Today, thanks to advances in #medicalscience, we know that prurigo nodularis (PN) involves a complex interplay between the immune and nervous systems, leading to severe and pathological itching. In an exciting #dermatology development, the @FDA has just approved the breakthrough treatment Nemluvio® (nemolizumab-ilto), which targets Interleukin (IL)-31, a key neuroimmune cytokine involved in the severe itching, inflammation, and fibrosis seen in PN. Nemolizumab, a humanized IgG2 monoclonal antibody, works by inhibiting IL-31 signaling. Its approval is backed by data from two successful Phase 3 #clinicaltrials: OLYMPIA 1 and OLYMPIA 2, involving 560 patients. Results showed a significant reduction in itch intensity and #skin clearance for many patients, marking a huge step forward in managing this challenging condition. Key Efficacy Results: OLYMPIA 1: 22% of patients on nemolizumab saw at least a 4-point reduction in itch intensity, compared to just 2% in the placebo group. OLYMPIA 2: 25% of patients on nemolizumab experienced similar improvements versus 4% on placebo. Advancements like these highlight the importance of continued #dermatologyresearch in the connection between the immune system and chronic conditions. This is an exciting development for #healthcare providers and patients alike, offering new hope for managing prurigo nodularis. #Dermatology #FrontierDermatology #FDAApproval #Nemluvio #Nemolizumab #PrurigoNodularis #Dermatology #HealthcareInnovation #SkinCondition #HealthySkin #SkinHealth #BetterSkin #SkinGlow #GlowingSkin #SkinGoals https://lnkd.in/gtv_QWrM

UCB Receives FDA Approval for BIMZELX® (bimekizumab-bkzx) HCP® as the first and only treatment targeting both IL-17A and IL-17F for adults with moderate to severe hidradenitis suppurativa (HS). This approval is supported by positive Phase 3 trial results showing significant and sustained improvements in disease signs and symptoms. Hidradenitis suppurativa is a chronic and debilitating condition with limited treatment options, and this approval marks a major step forward for patients.    BIMZELX is now the fifth FDA-approved indication for bimekizumab-bkzx in the U.S., further solidifying UCB's commitment to advancing care in IL-17 mediated diseases.   Read more: https://lnkd.in/eBmr4P7X   #Dermatology #hidradenitissuppurativa #HS #FDAapproval

Imagine integrating genetic testing and a comprehensive drug efficacy panel into your treatment plans. 🧬 Imagine detailed reports with recommended compounds based on efficacy levels. 💊 Imagine the transformative impact on your treatment outcomes. 🚀 Join our webinar to learn about this revolutionary approach through clinical cases. 🌟 #genetictesting #personalizedmedicine

Clinicians always need additional effective and safe therapies in their treatment toolbox. The recent publication of effectiveness and safety through 100 weeks of treatment with #risankizumab for the treatment of DMARD failure #PsoriaticArthritis patients is an important milestone ( DOI: 10.1007/s40744-024-00657-2 ). With “Keystone” levels of ACR20, ACR50, and ACR70 scores sustained through 2 years, and PASI90 responses consistent with what we have seen in the #Psoriasis studies ( DOI:10.1056/NEJMoa1607017 , DOI:10.1016/j.jaad.2023.07.1024 ) , and consistent safety data, the KEEPsAKE 2 results solidify risankizumab’s place in our PsA toolbox. #drugdevelopment #dermatology #clinicaltrials #clinicalresearch

💡Psoriasis Treatment is Evolving! 💡 Spherix Global Insights highlights the excitement around pipeline agents like Johnson & Johnson’s oral IL-23 asset, JNJ-2113, which reflects high expectations for it to capture significant market share, potentially outpacing other oral candidates and shifting the timelines for initiating biologic treatments. Competing with JNJ-2113 in the pipeline are several promising TYK2 inhibitors, including ESK-001 from Alumis, zasocitinib (TAK-279) from Takeda, and BMS-986322 from Bristol Myers Squibb. With patient preference shifting towards oral options, these innovative treatments could reshape the market and improve care. Read more: https://lnkd.in/e4JfAKMy #Psoriasis #Dermatology #EmergingTherapies #MarketResearch

🌟 Rare Disease Spotlight: Pemphigus 🌟 A disease that causes blistering of the skin and the inside of the mouth, nose, throat, eyes, and genitals. Pemphigus is an autoimmune disease in which the immune system mistakenly attacks cells in the top layer of the skin (epidermis) and the mucous membranes. 📌 People with the disease produce antibodies against desmogleins, proteins that bind skin cells to one another. When these bonds are disrupted, skin becomes fragile, and fluid can collect between its layers, forming blisters. ⚡ There are several types of pemphigus, but the two main ones are: 🔶 Pemphigus vulgaris, which normally affects the skin and mucous membranes such as the inside of the mouth. 🔶 Pemphigus foliaceus, which only affects the skin. 📌 There is no cure for pemphigus, but in many cases, it is controllable with medications. #Dermatology #AutoimmuneDiseases #Pemphigus #MedicalResearch

ANNOUNCEMENT / UPDATE JUNE 2024: Cassderma Rx has just completed the second round of pre-clinical wound healing studies. The previous study showed that two different formulations of CAS001 (drug + cell culture media gel) accelerated wound healing relative to untreated wounds.  This new study shows that the selected formulation had accelerated wound healing relative to vehicle (cell culture media gel).  No safety issues were observed.   * Cassderma Rx is continuing to make great progress towards helping individuals suffering from non-healing chronic wounds, which is still classified a global unmet need.    * Here is a graph from NIH Publication stating:            “Due to high costs, chronic wounds have become a substantial burden to healthcare systems.  More than half of the chronic wounds affect the foot area and are composed of diabetic foot  ulcers, venous ulcers and arterial ulcers. Furthermore, the annual mortality rate in patients with diabetic foot ulcers is about 11% and about 22% for those with an incident lower extremity amputation.” #research, hashtag hashtag #fda, hashtag hashtag #skin, hashtag hashtag #wounds, hashtag hashtag #dermatology, hashtag hashtag #pressureulcers, hashtag hashtag #burns, hashtag hashtag #diabetes

Under the motto “Uncovering the Broad Spectrum of Psoriatic Disease” the 7th World Psoriasis & Psoriatic Arthritis Conference took place last week in Stockholm. The focus of the conference is to improve the lives of patients living with psoriatic disease by sharing significant achievements in the prevention, diagnosis, and treatment. With PsorX-LabDisk, we support dermatopathologists in the differential diagnosis of psoriasis and eczema - as there are still up to 50% misdiagnoses of the two skin diseases due to overlapping clinical and histological appearances. However, the feedback from the dermatologists at the conference was clear: ❗This is not enough❗The test needs to be introduced into dermatologists' practices for use at the point of care. How good that work on it is already in full swing in the Dermagnostix R&D team!💪🚀 This feedback once again reinforces our belief in the urgent need for molecular diagnostics for inflammatory skin diseases - both for dermatologists and pathologists. 💡You want to be part of the #DermagnosticFuture? Schedule a meeting with us now to learn more about PsorX: https://lnkd.in/egn75BGc #MolecularDiagnostics #Psoriasis #PsorX #Dermatology #Innovation #IFPA